Trilaciclib在广泛期小细胞肺癌一线化疗中的骨髓保护:Ib/II期研究
该研究为Ib期开放标签剂量探索及II期随机双盲安慰剂对照试验,评估Trilaciclib联合依托泊苷/卡铂治疗初治广泛期小细胞肺癌的安全性与疗效。Trilaciclib改善了中性粒细胞、红细胞和淋巴细胞指标,≥3级不良事件发生率低于安慰剂,且未损害抗肿瘤疗效。
要点
- Trilaciclib可减轻化疗所致多系骨髓抑制。
- Trilaciclib组≥3级不良事件更少,无治疗相关≥3级事件。
- 抗肿瘤疗效指标与安慰剂组无显著差异。
核心结论
- Trilaciclib通过多系骨髓保护改善化疗耐受性,减少支持治疗和剂量降低,且不损害抗肿瘤疗效。
研究设计与样本
- Ib期开放标签剂量探索和II期随机双盲安慰剂对照研究,纳入初治广泛期小细胞肺癌患者,共122例入组,部分1和部分2分别有19例和75例接受研究药物。
主要发现
- Trilaciclib在中性粒细胞、红细胞和淋巴细胞指标上均见改善。
- Trilaciclib组≥3级不良事件发生率为50%,安慰剂组为83.8%,主要因血液学毒性减少。
- 未发生Trilaciclib相关的≥3级不良事件。
- Trilaciclib组与安慰剂组分别:ORR 66.7% vs 56.8%(P=0.3831);中位PFS 6.2 vs 5.0个月(HR 0.71;P=0.1695);OS 10.9 vs 10.6个月(HR 0.87;P=0.6107)。
临床怎么用
- 对于接受依托泊苷/卡铂化疗的广泛期小细胞肺癌患者,Trilaciclib可作为骨髓保护策略以减少血液学毒性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chemotherapy-induced damage of hematopoietic stem and progenitor cells (HSPC) causes multi-lineage myelosuppression. Trilaciclib is an intravenous CDK4/6 inhibitor in development to proactively preserve HSPC and immune system function during chemotherapy (myelopreservation). Preclinically, trilaciclib transiently maintains HSPC in G1 arrest and protects them from chemotherapy damage, leading to faster hematopoietic recovery and enhanced antitumor immunity. PATIENTS AND METHODS: This was a phase Ib (open-label, dose-finding) and phase II (randomized, double-blind placebo-controlled) study of the safety, efficacy and PK of trilaciclib in combination with etoposide/carboplatin (E/P) therapy for treatment-naive extensive-stage small-cell lung cancer patients. Patients received trilaciclib or placebo before E/P on days 1-3 of each cycle. Select end points were prespecified to assess the effect of trilaciclib on myelosuppression and antitumor efficacy. RESULTS: A total of 122 patients were enrolled, with 19 patients in part 1 and 75 patients in part 2 receiving study drug. Improvements were seen with trilaciclib in neutrophil, RBC (red blood cell) and lymphocyte measures. Safety on trilaciclib+E/P was improved with fewer ≥G3 adverse events (AEs) in trilaciclib (50%) versus placebo (83.8%), primarily due to less hematological toxicity. No trilaciclib-related ≥G3 AEs occurred. Antitumor efficacy assessment for trilaciclib versus placebo, respectively, showed: ORR (66.7% versus 56.8%, P = 0.3831); median PFS [6.2 versus 5.0 m; hazard ratio (HR) 0.71; P = 0.1695]; and OS (10.9 versus 10.6 m; HR 0.87; P = 0.6107). CONCLUSION: Trilaciclib demonstrated an improvement in the patient's tolerability of chemotherapy as shown by myelopreservation across multiple hematopoietic lineages resulting in fewer supportive care interventions and dose reductions, improved safety profile, and no detriment to antitumor efficacy. These data demonstrate strong proof-of-concept for trilaciclib's myelopreservation benefits. CLINICAL TRAIL NUMBER: NCT02499770.
引用
- Weiss JM, Csoszi T, Maglakelidze M, et al. Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial. Ann Oncol. 2019. PMID: 31504118. doi:10.1093/annonc/mdz278
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。